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ABSTRACT 
This study evaluated the usefulness of human papillomavirus (HPV) DNA testing and 
repeat cytology in triage of women referred to colposcopy in St. John's, Newfoundland 
with atypical squamous cells of undetermined significance (ASCUS) or low-grade 
squamous intraepithelial lesion (LSIL) cytology. Data were collected on the initial Pap 
abnormality that prompted referral, HPV test, repeat Pap test, and histology if biopsies 
were ordered. Of 447 women, 97 with ASCUS and 145 with LSIL had results for all 
tests. For ASCUS, HPV testing was I 00% sensitive for detection of underlying high-
grade intraepitheliallesions (HSIL) while reducing referrals to 44.3%. There would have 
been significant reductions in referrals among women ~30 years of age (74.3%) 
compared to younger women (27.4%). Nevertheless, in restricting HPV testing to 
women aged ~30 years, 8116 women with underlying HSIL would not have been referred 
to colposcopy. Repeat cytology was less sensitive (75%) for triaging all women. For 
LSIL, any method would have referred approximately 60% or more if a good sensitivity 
was achieved in any age group. For ASCUS, HPV triage appears to be more useful than 
repeat cytology. No useful triage strategy was identified for LSIL. 
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1.1 Rationale 
CHAPTER I 
INTRODUCTION 
Cervical cancer is a slow multi-step process and it is largely preventable with effective 
screening and adequate treatment (Franco, Duarte-Franco, & Ferenczy, 2001 ; Schiffman 
& Kjaer, 2003). The conventional approach to cervical cancer screening has been reliant 
on women presenting themselves for regular cervical cytology, also known as the 
Papanicolaou (Pap) test. The main purpose of the Pap test is to detect precancerous cell 
changes in the cervical epithelium, the cells that line the cervix, which may lead to 
cancer. If these abnormal cells are detected early, they can be treated before cancer 
develops. 
Research over the past 25 years or so has clearly established that certain oncogenic types 
of human papillomavirus (HPV) are the underlying necessary cause of cervical cancer 
(Bosch, Lorincz, Munoz, Meijer, & Shah, 2002; Walboomers et al. , 1999). Genital HPV 
infection is very common (Koutsky, 1997) and it is acquired with sexual activity (Kjaer 
et al. , 2001 ; Rylander, Ruusuvaara, Almstromer, Evander, & Wadell, 1994). The 
prevalence of HPV infection is highest among young women, reaching its peak in the 
early 20s, and declining with advancing age (Herrero et al., 2000; Ho, Bierman, 
Beardsley, Chang, & Burk, 1998; Ratnam et al. , 2000). In most cases, the infection is 
self-limited and completely asymptomatic without ever being clinically significant 
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(Evander et al., 1995; Franco et al., 1999; Hildesheim et al., 1994; Ho et al., 1998; 
Woodman et al., 2001). However, in some women, the infection can become persistent. 
It is the persistent HPV infection that increases the risk of precancerous abnormalities 
and its progression to cancer (Bosch & de Sanjose. 2003; Ho et al., 1998; Wallin et al. , 
1999). Regardless, cervical cancer is an uncommon outcome of HPV infection 
(Nobbenhuis et al., 1999). Since most HPV infections occur soon after initiation of 
sexual activity and are temporary, it is therefore those women over the age of 30, who are 
HPV positive that are most likely to represent persistent carriers (Bosch & de Sanjose, 
2003; Ho et al., 1998; Ho et al., 1995). These women are therefore at an increased risk 
for developing precancerous changes and cervical cancer. 
The Pap test has been proven to reduce the incidence and mortality of cervical cancer in 
developed countries (Anderson et a!, 1988; Canadian Cancer Statistics 2007; Gustafsson, 
Ponten, Zack, & Adami, 1997a). However, this test has limitations, the most serious 
being false negative results (Cuzick et al. , 2006). Further to this, there is remarkable 
variation in its performance indicators (Cuzick et al., 2006; Fahey, lrwig, & Macaskill, 
1995; Nanda et al. , 2000). A more precise and efficient method for screening is called 
for. Ideally, the Pap test should detect precancerous changes. Unfortunately, the 
majority of changes detected are not related to cervical cancer risk (Ho et al. , 1998; 
Kinney, Manos, Hurley, & Ransley, 1998; Solomon, Schiffman, & Tarone, 2001). In 
fact, the majority of all abnormal Pap reports, specifically atypical squamous cells of 
undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions 
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(LSIL), are minor cellular changes that are not associated with cervical cancer risk (Ho et 
al., 1998; Solomon et al., 2001). In most cases, these changes are not predictive of 
cervical cancer risk and will regress spontaneously (Ostor, 1993). However, because a 
small number of cases are associated with high-grade disease (ASCUSILSIL Triage 
Study (AL TS) Group, 2003a; Ho et al., 1998; Sherman et al., 2003), combined with the 
fact that Pap cytology is a screening test and not a diagnostic one, family physicians 
routinely refer women with these low-grade cytological abnormalities to gynecologists 
for further assessment or follow them up with repeat Pap testing at 4-6 month intervals 
over 2-3 years (Stuart et al., 2004). Referrals and repeat Pap testing involve delays in 
testing for those with true underlying disease, resulting in loss to follow-up and much 
anxiety on the part of these women, most of whom are not at risk (Bell et al. , 1995; 
Flannelly et al., 1994; Peters, Somerset, Baxter, & Wilkinson, 1999). 
Gynecologists routinely conduct additional tests, including an invasive and expensive 
procedure called a colposcopy on all those women referred for follow-up in order to 
identify the few of them who have high-grade disease. This testing may also involve 
invasive procedures such as biopsies or excisional procedures, so as to provide a 
histological diagnosis. At the end of this lengthy and costly process, most of these 
women with low-grade cytological abnormalities are not at risk for developing cervical 
cancer (Ho et al., 1998; Solomon et al., 2001 ). Since the majority of women who are 
found to have low-grade cytological abnormalities do not have an increased risk for 
developing cervical cancer, these repeat visits and procedures are unnecessary for most of 
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them. This represents poor resource utilization at a considerably unnecessary expense in 
health care costs, as well as unnecessary overtreatment with potential for negative health 
outcomes. In this context, recent studies indicate that HPV deoxyribonucleic acid (DNA) 
testing could be useful in identifying the small proportion of women who are at greatest 
risk of developing cervical cancer, while returning the majority to routine screening 
(Arbyn et al. , 2004; Arbyn et al., 2005; Manos et al., 1999; Solomon et al., 2001). 
The HPV DNA test is a sophisticated, molecular test that looks specifically for HPV 
DNA in cervical cells. To date, the Hybrid Capture II (HC-11) assay (Digene 
Corporation, Gaithersburg, Maryland, USA) is the most extensively used test. The HC-II 
assay is an in vitro, signal-amplified test for detecting DNA, in which ribonucleic acid 
(RNA) probes for HPV DNA are hybridized in solution with the sample DNA. It tests 
for 13 of the 15 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68. It 
is highly reproducible, easy to perform, and provides an objective result (Castle et al., 
2002; Castle, Wheeler, Solomon, Schiffman, & Peyton, 2004). Published studies have 
consistently reported a superior sensitivity of the HPV DNA test to cytology (Bigras & de 
Marva!, 2005; Clave! et al. , 2001; Cuzick et al., 2006; Cuzick et al., 2003; Mayrand et al., 
2007; Ratnam, Franco, & Ferenczy, 2000; Schiffman et al., 2000). 
In 1998, the Newfoundland Public Health Laboratory began offering the HPV DNA test 
on a routine basis through gynecologists across the Province as an adjunct test for further 
stratification of clarifying low-grade cytological abnormalities. The Canadian and 
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American guidelines now recommend the HPV DNA test as an adjunct test in triage of 
most low-grade Pap abnormalities, namely ASCUS (Provencher & Murphy, 2007; Stuat1 
et al., 2004; Wright et al., 2007). However, there is a difference in the recommendations. 
The American recommendation is for all women to be tested for HPV to clarify these 
abnormalities (Wright et al., 2007), while the Canadian recommendation is to test only 
women 30 years of age and older (Provencher & Murphy, 2007; Stuart et al., 2004). The 
rationale for this age-restricted testing recommendation is based on the fact that women 
30 years of age and older who are HPV positive most likely represent persistent carriers 
(Bosch & de Sanjose, 2003; Ho et al. , 1998), thereby reflecting an increased risk for 
developing cervical cancer. As well, because of the high prevalence of HPV in younger 
women, the specificity of the HPV test in these women is low (Sherman, Schiffman & 
Cox, 2002; Shlay, Dunn, Byers, Baron, & Douglas, 2000). In Canada and the United 
States, HPV testing is not recommended for women with LSIL Pap results, as it most 
likely represents a self-limited HPV infection; rather colposcopy is the recommended 
management option (Provencher & Murphy, 2007; Wright et al., 2007). Regardless, the 
usefulness of this test in the triage of low-grade Pap abnormalities in Newfoundland 
needs to be determined, and Canadian data is lacking. It has been recommended that 
more Canadian data be generated examining the usefulness of HPV DNA testing in 
triaging women with low-grade cytological abnormalities (Duarte-Franco & Franco, 
2004). 
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In this retrospective cohort study, we evaluated the usefulness of HPV DNA testing 
compared to repeat Pap cytology in the triage of low-grade cytological abnormalities in 
women referred to a colposcopy clinic in St. John's, Newfoundland. 
1.2 Objectives 
The objectives of the present study are as follows: 
1. To describe the association of HPV, repeat Pap cytology and histology results in 
women with low-grade cytological abnormalities. 
2. To assess the performance of the HPV DNA test in triage of women with low-
grade cytological abnormalities. 
3. To assess the performance of the repeat Pap test in triage of women with low-
grade cytological abnormalities. 
4. To compare the performance of both triage tests. 
5. To determine if age affects triage performance. 
6 
CHAPTER II 
LITERATURE REVIEW 
2.1 Burden of Cervical Cancer 
Globally, cervical cancer is the second most common cancer among women and the third 
most frequent cause of cancer-related deaths (Parkin, Bray, Ferlay, & Piscani, 2005). In 
2002, it was estimated that 493,000 new cases of cervical cancer were diagnosed 
worldwide, and that 274,000 women died from cervical cancer that same year. The 
disease incidence shows clear geographical variation. Eighty-three per cent of these 
cases were diagnosed in developing countries, where cervical cancer accounts for 
approximately 15% of cancers in women. It is the most common cancer in women in 
many regions, and is in fact the leading cause of cancer-related deaths among women in 
developing countries. In developed countries, however, cervical cancer accounts for only 
3.6% of cancers in women. 
Incidence and mortality rates in Canada are relatively low. Table 1 shows Canada' s 
incidence and mortality rates for cervical cancer and estimated numbers of new cases and 
deaths for 2007 (Canadian cancer statistics, 2007). Approximately 1350 new cases of 
cervical cancer were estimated to have been diagnosed in Canadian women in 2007, and 
an estimated 390 women died from the disease in the same year. The provinces with the 
highest incidence rates are Nova Scotia, Prince Edward Island and Alberta, with rates of 
10 per 100,000 women or greater; Newfoundland and Labrador has the highest mortality 
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Table 1: Estimated age-standardized incidence and mortality rates* for cervical 
cancer and estimated new cases and deaths in 2007 in Canada 
Province Incidence rate Mortality rate Estimated no. Estimated no. 
2er 100 000 2er 100 000 of new cases of deaths 
Newfoundland 8t 4 25t 10 
Prince Edward Island 10 3 10 5 
Nova Scotia 11 3 55 20 
New Brunswick 8 3 35 15 
Quebec 6 1 280 75 
Ontario 7 2 500 140 
Manitoba 7 2 45 15 
Saskatchewan 9 2 45 15 
Alberta 10 2 160 40 
British Columbia 7 2 170 50 
Canadat 7 2 1350 390 
* Rates are age-standardized according to the 1991 Canadian population. 
t Likely an underestimate of the number of cases for the years used to generate estimates. 
t Canada totals include provincial and territorial estimates. Territories are not listed separately due to small 
numbers. 
Source: Canadian Cancer Statistics 2007 
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rate in the country with 4 per 100,000 women, twice that of the Canadian rate; Quebec 
was the only province with an incidence rate below 7 per 100,000 women and a mortality 
rate below 2 per 100,000 women. Figures 1 and 2 show the time trends in age-
standardized incidence and mortality of cervical cancer for Canada since 1978. 
Generally, incidence and mortality rates of cervical cancer have declined in Canada 
during the last 50 years. 
The lower risk for cervical cancer in developed countries 1s a relatively recent 
phenomenon. This trend is attributed to effective cervical cytology screening 
programmes. Incidence rates of invasive cervical cancer have dropped by 70% since the 
introduction of cytological screening in some populations (Gustafsson et al. , 1997a). 
Before the introduction of screening programmes in the 1950s and 1960s, the incidence 
rates in most developed countries were similar to those found in developing countries 
today (Anderson et al , 1988; Gustafsson, Ponten, Bergstrom, & Adami, 1997b). In fact, 
screening for cervical cancer has been regarded as having a greater influence in reducing 
incidence and mortality than screening for any other cancer. 
2.2 HPV and Cervical Cancer 
2.2.1 HPV as Etiological Agent 
For more than a century, a link between cervical cancer and sexual activity has been 
suspected. In 1842, Rigoni-Stem reported that there was a relatively low incidence of 
cervical cancer in virgins and nuns and a high frequency of cervical cancer in prostitutes 
9 
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Figure 1: Age-standardized incidence rate for cervical cancer, Canada, 1978-2007 
Note: Rates are age-standardized according to the 1991 Canadian population. 
Source: Canadian Cancer Statistics 2007. 
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Figure 2: Age-standardized mortality rate for cervical cancer, Canada, 1978-2007 
Note: Rates are age-standardized according to the 1991 Canadian population. 
Source: Canadian Cancer Statistics 2007. 
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(Griffiths, 1991 ). Since that time, several epidemiological studies of women with 
cervical cancer showing strong associations with promiscuity and early age of first sexual 
intercourse further supported the notion that a sexually transmitted infection (STI) was 
involved in the development of cervical cancer (Brinton et al., 1987; Buckley, Harris, 
Doll, Vessey, & Williams, 1981 ; Harris et al., 1980; Kessler, 1977). Over the years, 
several infectious agents were put forth including syphilis, gonorrhea, and herpes simplex 
virus-2 (HSV -2) (zur Hausen, 1991 ). An association between the human papillomavirus 
(HPV) and cervical cancer was first suggested in the 1970s (Meisels, Fortin, & Roy, 
1977; zur Hausen, 1976). In recent years, research has now firmly shown that a subset of 
oncogenic types of HPV are the necessary, though not sufficient cause, of nearly all of 
cervical cancers (Bosch et al., 2002; Walboomers et al. , 1999) and its precursors (Cuzick 
et al., 2003; Elfgren et al., 2005; Kjaer et al., 1996; Kjaer et al., 2002; Koutsky et al., 
1992; Nobbenhuis eta!., 1999; Schiffman eta!., 1993; Schlecht et al., 2001). It is the 
first ever identified necessary cause of a human cancer (Walboomers et al., 1999). The 
International Agency for Research on Cancer (IARC) has coordinated 22 studies that 
have shown unequivocally that HPV can be detected in 99.7% of adequate cervical 
cancer specimens (Walboomers et al. 1999). 
2.2.2 Basic Virology 
HPV is a small, non-enveloped, double-stranded circular deoxyribonucleic acid (DNA) 
tumour virus, which is part of a family of viruses classified in the Papillomaviridae 
family (de Villiers, Fauquet, Broker, Bernard, & zur Hausen, 2004). All HPVs have the 
12 
same basic genomic organization and have been divided into three major portions based 
on their function. The first is a long control region, which is a non-coding region that 
regulates DNA replication. The second is an early transcription region that encodes 
transcripts (EI, E2, E4, E5, E6 and E7) for viral proteins involved in viral DNA 
replication, initiation of RNA transcription and disruption of the cell cycle. The third is a 
late transcription region that encodes transcripts (Ll and L2) for two viral proteins that 
make up the viral capsid (Munger et al. , 2004). 
2.2.3 Classification 
More than 120 different HPV types have been fully sequenced and characterized, with 
about 40 types infecting the epithelium of the human anogenital tract (de Villiers et al. 
2004). Based on IARC pooled data from 11 case-control studies of the association 
between cervical cancer and HPV infection from multiple countries (Munoz et al., 2003), 
15 HPV oncogenic types have been classified as high-risk for development of cervical 
cancer, 3 have been classified as probable high-risk, 12 have been classified as low risk, 
and 3 are considered to have undetermined risk (Table 2). The two most prevalent HPV 
types are I6 and I8, accounting for more than 60% of cervical cancer cases worldwide. 
HPV 16 accounts for approximately 50% of cases of cervical cancer, while HPV 18 
accounts for the other IO% to I2% (Munoz et al., 2003). In Canada, there are indicators 
that type 31 is the second most frequent genotype associated with precancer or cancer 
(Antonishyn, Horsman, Kelln, Saggar, & Severini, 2008). Types 6 and II are the most 
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Table 2: Classification of HPV types by the association with cervical cancer 
Risk classification HPV types 
High-risk 
Probable high-risk 
Low-risk 
Undetermined risk 
HPV = Human papillomavirus 
Source: Munoz et al., 2003. 
16, 18, 31 , 33, 35, 39, 45, 51 
52, 56, 58, 59, 68, 73, 82 
26, 53, 66 
6, 11 , 40,42, 43, 44, 54 
61 , 70, 72, 81 , CP6108 
34, 57, 83 
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frequently detected low-risk types and can often be detected in cases of genital warts 
(Brown, Schroeder, Bryan, Stoler, & Fife, 1999; Greer et al., 1995). 
2.2.4 Natural History of HPV 
HPV infections are among the most common STis worldwide (Koutsky, 1997; Schiffman 
& Kjaer, 2003). In fact, the lifetime risk of acquiring HPV is approximately 70% (Bosch 
& de Sanjose, 2003). HPV prevalence peaks in women during the early 20s (Ho et al. , 
1998; Ratnam et al., 2000) and drops to less than 10% in women over 30 years reaching 
about 5% or less with advancing age (Herrero et al., 2000; Ratnam et al. , 2000). In the 
vast majority of cases, infections are self-limited and asymptomatic, and resolve without 
treatment, cleared by the woman's immunity within one to two years (Evander et al. , 
1995; Franco et al., 1999; Hildesheim et al., 1994; Ho et al., 1998; Woodman et al. , 
2001 ). However, in a small proportion of women the infection can become persistent, 
and it is this persistent infection that predisposes to precancerous changes and cancer 
(Bosch & de Sanjose. 2003; Ho et al., 1998; Wallin et al., 1999). Since most HPV 
infections occur soon after initiation of sexual activity and are self-limited, women over 
the age of 30 include those who are more likely to be persistent carriers (Bosch & de 
Sanjose. 2003; Ho et al., 1998; Ho et al., 1995). 
2.2.5 Other Co-Factors 
Since only a minority of HPV infections will eventually lead to cervical cancer, HPV 
infection alone is not sufficient for cervical cancer development (Walboomers et al., 
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1999). Therefore, other factors must act as co-factors by influencing HPV persistence 
and cancer progression. Factors that have been established as co-factors include long-
term use of oral contraceptives (Moreno et al., 2002), smoking (International 
Collaboration of Epidemiological Studies of Cervical Cancer, 2006), high parity (Munoz 
et al ., 2002), and HIV co-infection (Palefsky & Holly, 2003). Probable co-factors include 
nutritional deficiencies (Garcia-Closas, Castellsague, Bosch, & Gonzalez, 2005) and 
other STis, namely HSV -2 (Smith et al., 2002) and Chlamydia trachomatis (Smith et a!. , 
2004). 
2.2.6 Pathogenesis of Cervical Cancer 
Cervical cancer is a proliferation of abnormal cells of the cervix, the lower part of the 
uterus. The cancer develops gradually over time, and in most cases, the cells go through 
a series of precancerous changes over a period of years before they become cancer (zur 
Hausen, 2002). The process of abnormal cell changes is initially limited to the cervical 
squamous epithelium, the cells that line the outer cervix. This precancerous overgrowth 
of cells is referred to as cervical intraepithelial neoplasia (CIN) or squamous 
intraepithelial lesions (SIL), and is classified into a three- or two-tier system. The CIN 
system has three categories according to the proportion of the epithelial layer showing 
CIN (Richart, 1973). CIN 1 refers to abnormal cells that occupy the lower one third of the 
cervical epithelium, and is most often indicative of a self-limited HPV infection. CIN2 
indicates that two thirds of the cervical epithelium is occupied by abnormal cells, and 
CIN3 indicates that the entire epithelial layer is occupied. The Bethesda system classifies 
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SIL as either low-grade SIL (LSIL) or high-grade SIL (HSIL), depending on the 
proportion of the epithelial layer showing SIL (Solomon et al., 2002). LSIL corresponds 
to CIN1 and HPV infection, and HSIL corresponds to CIN2, CIN3 and carcinoma in situ 
(CIS). 
The development of cervical cancer is a multi-step process. The major steps include 
HPV infection with a high-risk oncogenic type, persistence of the infection, progression 
from mild precancerous lesions (LSIL) to the more severe precancerous lesions (HSIL), 
and eventually cancer (Figure 3). Provided that the latter step has not yet occurred, prior 
to the development of cancer, this process is reversible, including clearance of HPV 
infection and regression of precancerous lesions (Ostor, 1993). It is generally accepted 
that HSIL has a higher likelihood of progression to cancer, so if diagnosed, HSIL are 
treated. The peak incidence of HSIL in women is between 25 to 29 years of age, a full 10 
years earlier than the peak incidence of cervical cancer (Kitchener, Castle, & Cox, 2006; 
Schiffman & Kjaer, 2003). Based on this, progression to cervical cancer takes 10 to 15 
years from the development of HSIL. 
2.2. 7 Role of HPV Oncoproteins 
In the process of HPV -induced carcinogenesis, the HPV genome integrates itself into the 
host chromosomes, leading to the continued expression of high-risk HPV oncoproteins, 
E6 and E7 (Munger et al., 2004). These oncoproteins interact with host cellular proteins 
that play central roles in the regulation of cell growth (zur Hausen, 2002). Consequently, 
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Figure 3: Natural history of cervical cancer 
Source: Schiffman & Kjaer, 2003. 
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the normal cell cycle is disrupted, resulting in genome instability, hyperproliferation, and 
ultimately immortal cells (Munger & Howley, 2002). 
High-risk E6 HPV proteins bind and direct the degradation of the cellular tumor 
suppressor protein p53 (Scheffner, Wemess, Huibregtse, Levine, & Howley, 1990; 
Wemess, Levine, & Howley, 1990). The p53 protein is expressed when the cell 
experiences stressful conditions, such as DNA damage, low levels of oxygen and 
nucleotide depletion or depletion of products or processes dependent on nucleotides 
(Graeber et al. , 1994; Linke, Clarkin, Di Leonardo, Tsou, & Wahl, 1996). The major 
events induced by p53 are cell growth arrest in order to allow DNA repair and survival 
or, elimination of cells with abnormal growth properties through programmed cell death 
(Munger & Howley, 2002). As a result of the disruption in the function ofp53 in the cell 
by the E6 protein, cell cycle arrest and programmed cell death are not possible. This 
leads to impairment of DNA repair mechanisms, accumulation of DNA mutations, 
leading to cellular transformation and ultimately malignancy (Gu, Pim, Labrecque, 
Banks, & Matlashewski, 1994; Havre, Yuan, Hedrick, Cho, & Glazer, 1995). 
E7 proteins of high-risk HPV s bind to, and inactivate, cellular tumor suppressor protein 
pRb (Dyson, Howley, Munger, & Harlow, 1989). The pRb protein acts as a regulator in 
cells about to progress into DNA replication by binding to E2Fs, a family of transcription 
factors that stimulate genes required for DNA replication and entry into the phase of 
replication (Weinberg, 1995). E7 binds to pRb, resulting in the release of E2Fs, causing 
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unscheduled progression through the cell cycle and leading to cell proliferation (Munger 
et al., 2001; zur Hausen, 2000). 
2.3 Screening 
Screening is defined as population-based testing of apparently healthy individuals in 
order to classify them as likely or unlikely to have a certain disease (Last, 2001). People 
identified to be at risk for the disease are further investigated through diagnostic tests. 
Those who are found to have disease are then treated. The goals of reducing morbidity 
and mortality among the screened are achieved by early diagnosis and treatment. To be 
suitable for screening, a disease has to go through a phase during which it would be 
detectable but unnoticed if not investigated. Further, the treatment should provide 
benefits as a result of detecting cases at an early stage. As was stated earlier, this is the 
case with cervical cancer screening. 
Sensitivity is the ability of the test to detect women who have a significant abnormality in 
the cervix while specificity is the ability of the test to correctly identify normal women. 
Both are important in screening programmes; the higher the quality of the test, the higher 
its sensitivity and specificity. Unfortunately, measures taken to increase sensitivity 
(reduce false negatives) often result in decreasing specificity (increasing false positives). 
Therefore, attempts to reduce the number of false negatives may lead to more normal 
women being recalled for repeat further testing. 
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2.3.1 Cytology 
2.3.1.1 Conventional Cytology 
The conventional Pap test has been regarded as the most successful screening tool for 
cancer in the history of medicine. Developed by Dr. George Papanicolaou in the 1920s 
(Vilos, 1999), the conventional Pap test involves taking a sample of cells from the lining 
of the cervix with a wooden spatula or a plastic brush. The cells are then transferred to a 
slide, stained and examined under a microscope to establish the presence or absence of 
abnormal cells. As this test is a screening tool, and not a diagnostic test, subsequent 
confirmation of these abnormalities is done by diagnostic histological examination of 
tissue biopsy via a colposcopic examination. These changes are often caused by HPV. 
The Pap test reporting classification has changed over time. Currently used in North 
America, the Bethesda System for classification and reporting of abnormal squamous and 
glandular cervical cytology was developed in 1988 (National Cancer Institute, 1989) and 
revised in 2001 (Table 3) (Soloman et al. 2002). It groups squamous cell abnormalities 
into four categories: atypical squamous cells (ASC), LSIL, HSIL, and cancer (Table 3). 
The ASC category is subdivided into 2 categories: ASC of unknown significance 
(ASCUS) and ASC in which high-grade lesions cannot be excluded (ASC-H). ASCUS 
may represent reactive changes that mimic, but are unrelated to, cellular changes caused 
by HPV, and HPV -associated changes, but are not distinguishable as a LSIL. ASC-H 
includes cellular changes that are suggestive of HSIL, but are lacking in the criteria to 
categorize it as such. As stated earlier, LSIL refers to abnormal cells that occupy the 
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Table 3: The 2001 Bethesda classification system for cervical squamous cell 
abnormalities 
Result Interpretation 
ASCUS (Atypical squamous cells of Squamous cells are abnormal, but may or 
undetermined significance) may not be precancerous 
ASC-H (atypical squamous cells, cannot Squamous cells are abnormal, but may or 
exclude HSIL) may not be HSIL 
LSIL (low-grade squamous intraepithelial 
lesions) 
HSIL (high-grade squamous intraepithelial 
lesions) 
Cancer 
Source: Solomon et al. , 2002. 
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Mildly abnormal squamous cells; changes 
are almost always due to temporary HPV 
infection 
Moderately to severely abnormal squamous 
cells 
Possibility of cancer cells present m the 
cervix is very high 
lower one third of the cervical epithelium, and is most often indicative of a self-limited 
HPV infection (Solomon et al. , 2002). HSIL refers to abnormal cells that occupy the 
lower two thirds or the entire cervical epithelium. 
2.3.1.2 Limitations of Conventional Cytology 
Although the conventional Pap test is important in its place as the most widely used 
cancer screening test in the world, and its impact on the incidence of cervical cancer, 
cervical screening, by conventional cytology, has considerable limitations. The sample 
must be representative of the cells that line the cervix. Often, an inadequate cell sample 
is taken, and/or the cells are not properly transferred or preserved on the slide. Also, the 
ability to fully evaluate the slide due to obscuring material, such as blood, mucus, 
overlapping cells, or inflammation, can also be a source of error. As well, the 
interpretation of changes in the cells is very subjective and poorly reproducible, even 
among expert cytologists (Stoler & Schiffman, 2001). Consequently, a wide range of 
false-negative and false-positive results has been reported (Cuzick et al. , 2006; Fahey et 
al. , 1995; Nanda et al. , 2000), which indicates that Pap screening can fail by under- or 
over-diagnosis. A meta-analysis of 62 studies conducted between 1984-92, reported the 
mean sensitivity was 58% (range = 11-99%) and mean specificity 68% (range = 14-97%) 
(Fahey et al. , 1995). In a more recent meta-analysis, Nanda et al. (2000) found the 
sensitivity of conventional cytology to be 47% and to range from 30-87%, while 
specificity was 95% ranging from 86-100%. 
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2.3.1.3 Liquid-Based Cytology 
In order to increase the sensitivity and specificity of cervical screenmg, alternative 
approaches have been proposed. Liquid-based cytology (LBC) is an improved method of 
preparing cervical samples for cytological examination. Two technologies are available: 
SurePath (BD TriPath Imaging Inc, Burlington, North Carolina, USA) and ThinPrep 
(Halogic Cytyc Corporation, Boxborough, Massachusetts, USA). It is a modification of 
the conventional Pap test, in which slides are not prepared at the time of collection. 
However, specimens are collected like a conventional Pap test. The ability to interpret 
the slide is improved because this approach ensures better specimen yield, the cells are 
more representative and randomized, and there is less obscuring material such as blood, 
mucus and inflammation. This leads to a better quality smear, therefore reducing the 
number of unsatisfactory reports (Kamon et al. , 2004). Several smears can be made and 
tested from one sample and the residual fluid is also suitable for ancillary testing, such as 
those for HPV DNA and other STis. However, despite these advancements in cytological 
screening for cervical cancer, LBC is still limited by moderate sensitivity, low 
reproducibility, and the subjective nature of the interpretation of results. 
2.3.2 HPV DNA Testing 
HPV DNA testing relies on molecular techniques to detect HPV in cervical specimens. 
There are currently two techniques available to test for the majority of high-risk HPV 
types responsible for the development of cervical cancer. 
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The first category is the signal-amplified nucleic assay, and to date, the Hybrid Capture II 
(HC-II) assay (Digene Corporation, Gaithersburg, Maryland, USA) is the most 
extensively used. It tests for 13 of the 15 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 68. The HPV DNA test is a molecular test to detect HPV DNA in 
infected cells, in which RNA probes for target HPV DNA are hybridized in solution with 
the sample DNA. 
The second category is the target-amplified assay, such as the polymerase chain reaction 
(PCR) technique. This technique produces highly concentrated samples of specific HPV 
DNA sequences which are then probed to identify the HPV types present. These types of 
assays require very small amounts of cervical specimen to detect HPV DNA and in fact 
can identify as few as 1 0-100 copies of HPV genome. 
Unlike the Pap test, HPV DNA testing is objective and highly reproducible (Castle et al. , 
2002). Since HPV is the necessary cause of cervical cancer, screening for HPV 
specifically is significantly more sensitive than the Pap test to detect pre-cancerous 
lesions and cervical cancer (Bigras & de Marva), 2005; Clave) et al., 2001; Cuzick et al., 
2006; Cuzick et al., 2003; Mayrand et al., 2007; Ratnam et al., 2000; Schiffman et al., 
2000). A recent meta-analysis assessed the value of HPV DNA testing compared to the 
Pap test in countries in North America and Europe with well-established cytology-based 
screening programmes (Cuzick et al., 2006), using histology as the gold standard. Their 
conclusion was that the sensitivity of cytology for detecting underlying HSIL or cancer 
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was substantially less than for HPV DNA testing with considerable variation between 
studies. The overall sensitivity of cytology was 53% (95% CI = 48.6-57.4) with a wide 
range from 18.6% to 76. 7%, reflective of the interpretative nature of the test. HPV DNA 
testing was consistently very sensitive in all studies, with an overall sensitivity for HSIL 
or worse of 96.1% (95% CI = 64.2-97.4). However, the overall specificity of HPV DNA 
testing was lower than that of cytology (90.7%; 95% CI = 90.4-91.1 and 96.3%; 95% CI 
= 96.1-96.5 respectively). A recently published Canadian study of 10,154 women also 
suggests that HPV DNA testing has greater sensitivity for detecting HSIL, as compared 
to Pap testing (Mayrand et al., 2007). Again, using histology as the gold standard, the 
authors found that the sensitivity of HPV DNA testing was 94.6% (95% CI = 84.2-1 00), 
while the sensitivity of Pap testing was 55.4% (95% CI = 33.6-77.2). The specificity of 
HPV DNA testing was 94.1% (95% CI = 93.4-94.8), which was lower than that of Pap 
testing (96.8%; 95% CI = 96.3-97.3). 
2.3.2.1 Clinical Applications of HPV DNA Testing 
Considering the limitations of Pap cytology and the fact that HPV is present in virtually 
all cervical cancers and pre-cancerous lesions, it has been suggested that detection of 
high-risk HPV could be useful in three clinical applications: a) as a primary screening test 
used alone or in combination with a Pap test to detect pre-cancerous lesions; b) as an 
adjunct test in triage of low-grade cytological abnormalities to identify women who need 
referral for diagnosis and treatment; and c) as a follow-up test for women who have been 
treated to predict cure or failure of treatment (Cuschieri & Cubie, 2005). The most 
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recommended clinical application of HPV testing at this time is in triage of specific low-
grade cytological abnormalities, namely ASCUS. 
2.3.3 Low-Grade Cytological Abnormalities 
Low-grade cytological abnormalities, as interpreted by the Pap test, are the most common 
Pap abnormalities (Solomon et al., 2002). They include ASCUS and LSIL. As described 
previously, ASCUS is an equivocal result that may encompass both reactive changes that 
mimic, but are unrelated to, HPV and HPV -associated cell abnormalities but fall below 
the diagnostic threshold for a definitive diagnosis of LSIL. It is difficult to reliably 
distinguish between the two conditions (Pitman, Cibas, Powers, Renshaw, & Frable, 
2002; Stoler & Schiffman, 2001; Sherman et al., 1994). It is the most common 
cytological abnormality, accounting for up to two-thirds of all reported Pap abnormalities 
(Solomon et al., 2002). LSIL results represent low-grade cytological abnormalities that 
are due to HPV infections that most often resolve spontaneously. However, because the 
Pap test is a screening tool, and not a diagnostic test, a small proportion of women with 
these low-grade cytological abnormalities results will have underlying HSIL or cancer by 
histology (Davey, Woodhouse, Styer, Stastny, & Mody, 2000). It has been reported that 
approximately 7% of women with ASCUS Pap results and 15% of women with LSIL Pap 
results have underlying HSIL or cancer (Davey et al. , 2000; Kinney et al. , 1998; Shlay et 
al. , 2000). Because the prevalence of low-grade cytological abnormalities is the highest 
of all abnormal Pap categories, they are the source of the majority of histologically 
confirmed HSIL and cancer. A substantial proportion of HSIL and cancer occurs among 
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women presenting with these low-grade Pap results (Kinney et al., 1998). This creates a 
dilemma for clinical management; follow-up or further testing is necessary to identify 
those at greatest risk; however, it should not result in over referring and over diagnosing, 
leading to increasing costs and patient anxiety. 
2.3.3.1 Management Options 
The management of women with ASCUS and LSIL is problematic because only a small 
proportion will have or progress to HSIL and cancer. Until recently, management 
options of women with low-grade cytological abnormalities were limited to immediate 
referral to colposcopy or repeat Pap testing at four to six month intervals until two 
consecutive normal results were obtained, with immediate colposcopy if ASCUS or more 
significant cytologic abnormalities were reported on any subsequent tests (Stuart et al., 
2004). Both options require repeated clinic visits, patient adherence, and represent poor 
resource utilization and potential for unnecessary treatment, not to mention considerable 
anxiety. HPV DNA testing for the triage of these women has been a subject of great 
interest in the last decade (Arbyn et al., 2004; Arbyn et al., 2005; ALTS Group, 2000; 
Manos et al. , 1999; Schiffman & Adrianza, 2000; Solomon et al., 2001). 
2.3.3.2 Triage 
Since the evolution of HPV DNA testing, many studies have evaluated its role in the 
triage of women with low-grade cytological abnormalities. However, most notably, two 
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landmark studies have contributed substantially to our knowledge of the value of HPV 
DNA testing in the follow-up of low-grade cytological abnormalities. 
In the first study, Manos et a!. (1999) carried out an observational study in Northern 
California comparing HPV DNA testing to repeat Pap testing in a sample of 995 women 
with ASCUS. All women had specimens taken for a repeat Pap test and HPV DNA 
testing, followed by a colposcopically-directed biopsy to confirm the diagnoses. The 
gold standard was a histological diagnosis of HSIL or cancer, as the current clinical 
practice is to treat histologically confirmed HSIL, in addition to cancer. The sensitivity 
of the HPV DNA test was 89.2% for detection of underlying HSIL or cancer. This was 
higher than repeat Pap testing at an ASCUS threshold of referral, which had a sensitivity 
of 76.2%. However, the specificity of HPV DNA testing was similar to that of repeat 
cytology (64.1% and 63.8%, respectively). It was estimated that triage based on HPV 
DNA testing or on repeat Pap testing with referral to colposcopy set at a repeat Pap result 
interpreted as ASCUS or more severe, would have resulted in approximately the same 
number of referrals for colposcopy (40%). The authors concluded that for women with 
ASCUS Pap results, a single HPV DNA test can help identify the majority of women 
with underlying HSIL or cancer, thereby replacing the practice of repeated cytology 
following and ASCUS diagnosis. 
In the second study, The National Cancer Institute of America initiated the ASCUS LSIL 
Triage Study (AL TS) to evaluate the management of women with ASCUS or LSIL Pap 
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results (Schiffman & Adrianza, 2000). It is the largest study, to date, examining HPV 
DNA testing as a way of triaging women with low-grade cytological abnormalities. 
ALTS compared three management strategies, namely referral for immediate colposcopy 
(considered to be the reference standard), HPV DNA triage with referral if positive, or 
triage based on repeat Pap testing with referral set at a repeat Pap result of ASCUS or 
greater. They enrolled 3,488 eligible women with ASCUS and 1,572 women with LSIL, 
and randomized them to one of the three management strategies. The gold standard was 
histologically confirmed HSIL or cancer. In women with ASCUS cytology, the 
sensitivities of immediate colposcopy, HPV DNA triage, and repeat Pap were 100, 95.9, 
and 85.0%, respectively (Solomon et al., 2001). Compared to all women being sent to 
immediate colposcopy, just over half (56.1 %) of the women having HPV DNA testing 
would have been referred to colposcopy, and 58.6% of the women having a single repeat 
Pap test would have been referred. The HPV DNA test showed a greater sensitivity for 
detection of histologically confirmed HSIL or cancer than a single repeat Pap at a 
threshold for referral of ASCUS or worse (95.9% and 85.0%, respectively), and a 
comparable specificity ( 48.4% and 44.7%, respectively). The authors concluded that 
HPV DNA testing is an option for managing women with ASCUS to determine if 
colposcopy is warranted. Nevertheless, the referral rate of women by HPV DNA testing 
is still high compared to the low percentage of true HSIL diagnosed in women with 
ASCUS, but is better than that of repeat cytology with the need for multiple repeat visits 
and multiple costs associated with further testing. 
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In women with LSIL Pap results, HPV DNA was detected in 82.9% (AL TS Group, 
2000). Despite the sensitivity of this approach, the high prevalence of HPV DNA in this 
group would not reduce referrals, clearly limiting its practicality and cost-effectiveness as 
a triage test. The authors concluded that HPV DNA testing would be ineffective in 
triage. The AL TS Group (2003b) also carne to the same conclusion that repeat cytology 
was not justified, as over 80% of women at the ASCUS threshold would have been 
referred. Direct referral to colposcopy was suggested as the best management option for 
this group of women (ALTS Group, 2000; ALTS Group, 2003b). 
A recent systematic review of I 0 published studies also carne to the conclusion that due 
to the low specificity (28.8%; 95% CI = 22.0-36.0) of the HPV DNA test in women with 
LSIL cytology, as a result of the high HPV positivity (77.2%), the test would not be 
effective (Arbyn et al., 2005). However, in a study conducted in Israel of 503 women, 
Fait et al. (2000) reported that a positive HPV DNA test result had a sensitivity of 88.2% 
and a specificity of 94.7% for detecting histologically confirmed HSIL in women with 
two consecutive LSIL Pap test results. They concluded that HPV DNA testing could 
have a place in the triage of these women, but suggested that the test be used after one 
cytology result of LSIL rather than two. 
A recent meta-analysis of 8 published studies also examined HPV DNA testing compared 
with repeat Pap testing for triage of ASCUS Pap results (Arbyn et al., 2004). It was 
concluded that HPV DNA testing has a significantly higher sensitivity than repeat Pap 
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cytology at a referral threshold of ASCUS (94.8%; 95% CI = 92.7-96.9 and 81.8%; 95% 
CI = 73.5-84.3 respectively) for detection of HSIL and cancer, while maintaining similar 
specificity (67.3%; 95% CI = 58.2-76.4 and 57.6%; 95% CI = 49.5-65.7 respectively). 
In one of few Canadian studies conducted in this area, Lytwyn et al. (2000) examined 
HPV DNA testing and repeat Pap testing in 212 women from Ontario with ASCUS and 
LSIL. They found the HPV DNA test to be more sensitive (87.5%) than repeat Pap 
testing (55.6%) at an ASCUS threshold for referral in these women. However, they 
reported the performance of the tests without distinguishing between women with 
ASCUS or LSIL. 
Kim, Wright, & Goldie (2002) reported a modeling analysis of immediate colposcopy, 
HPV DNA testing, and repeat Pap cytology for managing ASCUS cytology. They came 
to the conclusion that HPV triage is more cost-effective than repeat Pap cytology or 
colposcopy, while maintaining the same health benefits as immediate colposcopy. 
However, even in the context of ASCUS cytology and HPV DNA testing, the specificity 
is somewhat low. Only about one quarter of women with ASCUS cytology and who are 
HPV positive will have underlying HSIL. 
Because the specificity of the HPV DNA test is relatively low, it is a priority to identify 
strategies that could be used to improve it. Since HPV prevalence varies with age, the 
specificity of the HPV DNA test in triage depends on age (Arbyn et al., 2006). 
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Therefore, using age-restricted HPV DNA testing could possibly improve specificity, as 
well as significantly reduce the number of referrals to colposcopy, while maintaining test 
sensitivity. A few studies have examined the performance of HPV DNA testing, stratified 
by age. The AL TS data were further analysed by age group to compare test performance 
(Sherman et al., 2002). In women with ASCUS, HPV prevalence was much lower in 
women older than 28 years of age (31.2%) compared with younger women (more than 
65%), which could represent a significant cost saving in referrals. The sensitivity of the 
HPV test varied minimally between age groups (range, 93.9% to 97.8%). In women with 
LSIL, more than 74% would have been referred regardless of the age group under which 
they fell. In another study, Shlay et al. (2000) compared the performance of HPV DNA 
testing in women with ASCUS in two age categories. In women 30 years of age and 
older, only 20.2% would have been referred to colposcopy, compared to 48.7% of 
women younger than 30 years of age. The sensitivity was somewhat lower in older 
women (85.7% in women~ 30 years and 100% in women< 30 years, respectively). The 
specificity of HPV DNA testing was significantly higher in older women (83.9%) versus 
younger women (57.4%) (P < 0.01). However, if HPV DNA testing had been restricted 
to women 30 years and older, 8 women younger than 30 years of age with underlying 
HSIL would have been missed. 
2.3.3.3 HPV Triage Recommendations for Low-Grade Cytological Abnormalities 
The Pan-Canadian Forum on Cervical Cancer Prevention and Control in 2004 
recommended that HPV testing should be used to triage women 30 years and older with 
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ASCUS cytology (Stuart et al., 2004). No recommendation was given for women with 
LSIL cytology with respect to HPV DNA testing, but it was recommended that a national 
consensus management algorithm be developed. Canadian Consensus Guidelines on 
HPV published in 2007 also state that HPV DNA testing is recommended for women 
aged 30 years or more with ASCUS cytology (Provencher & Murphy, 2007). However, 
it is recommended that HPV testing should not be done on LSIL cytology. 
Largely based on the AL TS-trial findings, the American Society for Colposcopy and 
Cervical Pathology (ASCCP) Concensus Conference 2006 recommended that a 
programme of repeat Pap tests, colposcopy, or HPV DNA testing are all acceptable 
methods of management for ASCUS cytology (Wright et al., 2007). However, when 
reflex HPV DNA testing is available, it is the preferred approach, as it makes a second 
clinic visit unnecessary. For women with LSIL cytology, colposcopy is the 
recommended management option. 
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CHAPTER III 
MATERIALS AND METHODS 
3.1 Study Population and Data Collection 
The Health Sciences Centre in St. John's, Newfoundland, currently operates a referral 
colposcopic clinic. The gynecologists regularly see women who are referred with 
abnormal Papanicolaou (Pap) reports. These gynecologists routinely use the human 
papillomavirus (HPV) deoxyribonucleic acid (DNA) test as part of their standard patient 
care, in addition to repeat Pap tests, colposcopies, and biopsies. 
In the present study, data were collected on 447 women with low-grade Pap 
abnormalities, namely atypical squamous cells of undetermined significance (ASCUS) or 
low-grade squamous intraepitheliallesions (LSIL), referred to the above clinic during the 
period of November 2003 to March 2006. Data were systematically collected on the 
initial Pap abnormality that prompted referral, the results of the HPV DNA test and 
repeat Pap test, along with histology, if biopsies were taken. Cervical specimens for HPV 
DNA testing and Pap testing were either co-collected using separate cytobrushes, or 
collected in liquid-based cytology (LBC) with reflex testing. All data were retrieved 
from the Meditech laboratory information system (Boston). Data analysis was limited to 
those women who had HPV DNA testing and repeat Pap testing at the colposcopy clinic, 
and for whom histology results were available within one year of follow-up. 
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3.2 Ethics 
Ethics approval for the present study was obtained from the Memorial University of 
Newfoundland Faculty of Medicine, Human Investigation Committee (Appendix A). All 
files are kept in a locked storage cabinet in a locked room. All computer files are 
password protected. 
3.3 Cytology 
All women had a conventional Pap test done within one year prior to referral, performed 
by community physicians. These baseline smears were interpreted in four different 
cytology laboratories in Newfoundland, and were used as the prompting referral Pap 
smear diagnoses. 
The repeat Pap specimens at referral were collected using either conventional Pap test 
methods or LBC. In the conventional Pap test method, a cervical sample was taken with 
a wooden spatula and/or cytobrush. The cells were then directly transferred to a glass 
slide and immediately sprayed with an alcohol fixative. The collection device was 
discarded and the sample was sent to the regional cytology laboratory, Eastern Health, in 
St. John' s, where it was processed and interpreted by qualified cytotechnologists and 
pathologists. 
For the LBC portion of the study, SurePath System (BD TriPath Imaging Inc, Burlington, 
North Carolina, USA) was used. Cervical samples were collected using a plastic broom 
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and placed into a vial of SurePath preservative fluid. The collection devices were 
detached from the handle and were left in the vial. The vial was then sent to the regional 
cytology laboratory in St. John' s for processing. In the laboratory, the preserved sample 
was mixed by vortexing. The cell suspension was then layered onto a density reagent in a 
centrifuge tube; centrifugation of the suspension removed debris, mucus, and excess 
inflammatory cells from the sample, producing a concentrated pellet of cells. After 
centrifugation, the pelleted cells were resuspended, mixed and transferred to a settling 
chamber mounted on a glass slide. The cells were sedimented by gravity, stained and 
examined under a microscope. The residual sample was forwarded to the Public Health 
Laboratory for HPV DNA testing. Technologists at the regional cytology laboratory 
performed all cytology. Cervical cytology results were classified according to the 2001 
Bethesda System (Solomon et al., 2002) by qualified cytotechnologists and pathologists. 
3.4 HPV DNA Testing 
HPV DNA testing was done usmg the Hybrid Capture II (HC-11) test (Digene 
Corporation, Gaithersburg, Maryland, USA). For this, cervical specimens collected in 
either the Digene specimen transport medium (STM) or the leftover SurePath media were 
used. Specimens collected in the SurePath media were validated for use for HPV DNA 
testing. STM specimens were processed according to the manufacturer's instructions for 
HPV testing. SurePath specimens were centrifuged in STM and processed as in the STM 
protocol. 
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The HC-11 assay detects the presence of DNA by ribonucleic acid (RNA)-DNA 
hybridization technology using an RNA probe cocktail. The RNA probe cocktail 
recognizes a wide range of high- and low-risk HPV types (high-risk: 16, 18, 31, 33, 35, 
39, 45, 51 , 52, 56, 58, 59, 68; low-risk: 6, 11 , 42, 43, 44). The study used the high-risk 
probe cocktail to detect 13 high-risk types. The test procedure is as follows: The DNA 
was extracted and denatured. The RNA probes then hybridized in solution with the 
denatured target HPV DNA from the specimen. The DNA-RNA hybrids were 
subsequently bound to the surface of a micro plate well, which is coated with antibodies 
specific for DNA-RNA hybrids. HPV positive wells were detected with alkaline 
phosphatase-conjugated antibodies specific for DNA-RNA hybrids in combination with a 
chemiluminescent substrate. The light emitted is measured in relative light units (RLU) 
using a plate luminometer. The intensity of light measured is proportional to the amount 
of target DNA in the specimen. A positive test was defined as an RLU measurement of 
1 pg/mL HPV DNA. That level corresponds to approximately 5000 genomic copies of 
HPV DNA in the test. Samples with less than 1 pg/mL oncogenic HPV DNA indicate 
the specimen is negative for the 13 HPV DNA types included in the test or that the HPV 
DNA levels for these 13 types is below the detection threshold of this assay. A positive 
result indicates the presence of at least one of the types of HPV in the panel, but does not 
specify which of the types are present. Technologists at the Public Health Laboratory, St. 
John' s, tested all specimens. 
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3.5 Histology 
Histology was performed at the discretion of the managing clinicians. Standard 
processing included three levels for each biopsy and further testing as deemed 
appropriate by the pathologist. Interpretation of hematoxylin and eosin slides was given 
by qualified pathologists. In assessing the performance of the Pap and HPV tests, 
histological diagnoses were used as the gold standard. We used squamous intraepithelial 
lesion (SIL) nomenclature to describe histological outcomes (Solomon eta!., 2002). We 
considered only the clinical outcome of high-grade squamous intraepithelial lesions 
(HSIL) or worse, as it is standard practice to treat a histological diagnosis of HSIL or 
more severe (Wright et a!. , 2007). 
3.6 Data Analysis 
This analysis examines the performance of repeat Pap cytology and HPV DNA testing 
using a histological diagnosis of HSIL or worse as the primary study endpoint. Data for 
the women with ASCUS and LSIL referral Pap test results were analysed separately. 
3.6.1 Definition of Variables 
Cervical Cytology - A categorical variable reported in this format. 
Negative 
ASCUS 
ASC-H 
Negative for malignancy 
Atypical Squamous Cells of Undetermined Significance 
Atypical Squamous, Cannot Exclude HSIL 
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LSIL Low-grade Squamous Intra-epithelial Lesion 
HSIL High-grade Squamous Intra-epithelial Lesion 
The variable was dichotomized for analysis of performance indicators in two different 
ways. The performance of repeat Pap cytology was evaluated at two thresholds for 
colposcopy referral: 1) ASCUS or more severe interpretation and 2) LSIL or more severe 
interpretation. 
HPV DNA - A categorical variable reported as a semi-quantitative measure in RLU by 
the laboratory. 
Negative 
Positive 
Negative or below detection threshold for all of 13 high-risk types listed 
earlier. 
;:::1.0 RLU. 
HPV DNA testing was assessed at one threshold for a positive result: ~1.0 pg/mL. 
Histology - A categorical variable reported in this format. 
Negative 
LSIL 
HSIL 
Negative for malignancy 
Low-grade Squamous Intra-epithelial Lesion 
High-grade Squamous Intra-epithelial Lesion 
The variable was dichotomized as follows for analysis: 
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Negative 
Positive 
:5 LSIL 
~HSIL 
However, because there were no cases of cancer, we refer to the primary end-point as 
HSIL as there is a general consensus that this SIL has a strong risk for progression to 
cancer and therefore requires treatment (Wright et al., 2007). 
Age - Provided by the laboratory and categorized according to the format that is 
commonly reported in the literature and the recommended age threshold for HPV triage 
in women with ASCUS cytology by the Pan-Canadian Forum on Cervical Cancer 
Prevention and Control (Stuart et al., 2004) and the Canadian Consensus Guidelines on 
Human Papillomavirus (Provencher & Murphy, 2007). 
Age< 30 
2 Age~ 30 
3.6.2 Statistical Methods 
Statistical analyses were performed using SPSS® and SAS® software packages (SPSS, 
version 13.0 and SAS, version 9.1). Conventional 2 x 2 contingency tables were 
compiled and analysed to assess the association between categorical variables. For these 
analyses, the Pearson chi-square test was used, and in cases where the expected cell count 
for at least one cell was less than five, Fisher' s exact test was used. Performance 
indicators of sensitivity, specificity, positive predictive value (PPV) and negative 
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predictive value (NPV) for detecting histologically confirmed HSIL based on repeat 
cytology and HPV DNA testing were calculated using the conventional 2 x 2 contingency 
tables, with a 95% confidence interval (CI) around the estimates. Because the study 
sample size was small, 95% exact Cis based on binomial probabilities were calculated 
(Deeks & Altman, 1999). If Cis did not overlap, differences between proportions were 
considered statistically significant. All statistical tests were two-sided and the values P S 
0.05 were regarded as statistically significant. 
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4.1 Introduction 
CHAPTER IV 
RESULTS 
In this retrospective cohort study, we collected data on women who were referred to a 
colposcopy clinic in St. John's with a prompting Papanicolaou (Pap) test result of 
atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous 
intraepithelial lesions (LSIL). During the study period, data were collected from a total 
of 447 women, representing 186 referred to the clinic with ASCUS cytology and 261 
with LSIL cytology. Since not all women had a human papillomavirus (HPV) 
deoxyribonucleic acid (DNA) test, for further analyses we considered only those that had 
a valid HPV DNA test. Study inclusion criteria also entered only those with a repeat Pap 
test at enrollment and histology within a year of enrollment. This reduced the total 
numbers evaluated to 242, 97 women with ASCUS and 145 with LSIL, and this 
constituted the study population. The study analyzed the data to explore the association 
of HPV, repeat cytology and histology results in these women. The study also analyzed 
the data to assess the performance of HPV DNA testing in triage of women with low-
grade cytological abnormalities, comparing it with that of repeat Pap testing, while 
determining if age affects test performance. 
In the 97 women referred with an ASCUS result, the mean age was 36.3 years (ranging 
from 18 to 64), 36.1% were under 30 years of age, and 63.9% were 30 years of age and 
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older. In the 145 women referred with an LSIL result, the mean age was 27.8 years old 
(range 16 to 58), 70.3% were under 30 years of age, and 29.7% were 30 years of age and 
older. 
4.2 HPV Prevalence 
The overall HPV prevalence in women referred with ASCUS was 44.3% (43/97). When 
stratified by age, in women referred with an ASCUS Pap, HPV prevalence was 
significantly higher among women less than 30 years of age (74.3%) as compared with 
those beyond that age (27.4%) (P < 0.001). The prevalence of HPV among women 
referred to the colposcopy clinic with a baseline Pap of ASCUS or LSIL, stratified by 
age, is shown in Table 4. In women referred with LSIL cytology, 79.3% (1151145) tested 
positive for HPV. There was no significant difference in the prevalence of HPV among 
younger and older women referred with LSIL when stratified by age (P = 0.065). 
However, the prevalence of HPV was significantly higher in women with a baseline Pap 
result ofLSIL (79.3%) than in women with a baseline Pap result of ASCUS (44.3%) (P < 
0.001). 
4.3 Association of HPV with Repeat Pap Cytology 
The association between HPV and the repeat Pap test result for the 97 women referred 
with ASCUS cytology is presented in Table 5. Although all of these women had an 
ASCUS Pap in the community-based routine Pap screening, the repeat Pap test results at 
referral were heterogeneous. The repeat Pap test was negative in 59 (60.8%) women, 
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Table 4: Association between baseline Pap and HPV result 
Baseline Pap HPV result 
Positive Negative Total 
Age <30 years 
ASCUS 26 (74.3%) 9 (25.7%) 35 
LSIL 85 (83.3%) 17(16.7%) 102 
Age 2:3 0 years 
ASCUS 17 (27.4%) 45 (72.6%) 62 
LSIL 30 (69.8%) 13 (30.2%) 43 
All ages 
ASCUS 43 (44.3%) 54 (55.7%) 97 
LSIL 115 (79.3%) 30 (20.7%) 145 
ASCUS = Atypical squamous cells of undetermined significance; HPV = Human papillomavirus; LSIL = 
Low-grade squamous intraepitheliallesions; Pap = Papanicolaou 
P < 0.00 I from Pearson chi-square test for prevalence of HPV in women :::;29 years versus 2:30 years who 
were referred with ASCUS. 
P = 0.065 from Pearson chi-square test for prevalence ofHPV in women S29 years versus 2:30 years who 
were referred with LSIL. 
P < 0.00 I from Pearson chi-square test for prevalence of HPV in women with LSIL versus ASCUS. 
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Table 5: Association between repeat Pap and HPV DNA result in women referred 
with ASCUS Pap results 
Repeat Pap HPV result 
Positive Negative Total 
(row%) (row%) (column%) 
Negative 11 (18.6) 48 (81.4) 59 (60.8) 
ASCUS 11 (78.6) 3 (21.4) 14 (14.4) 
LSIL 15 (83.3) 3 (16.7) 18 (18.6) 
HSIL 6 (100.0) 0 (0.0) 6 (6.2) 
Total 43 (44.3) 54 (55.7) 97 (100.0) 
ASCUS = Atypical squamous cells of undetermined significance; DNA = Deoxyribonucleic acid; HPV = 
Human papillomavirus; HSIL = High-grade squamous intraepitheliallesion; LSIL = Low-grade squamous 
intraepitheliallesion; Pap = Papanicolaou 
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ASCUS in 14 (14.4%), LSIL in 18 (18.6%) and high-grade squamous intraepithelial 
lesions (HSIL) in 6 (6.2%). The prevalence of HPV increased with the increasing 
severity of the repeat Pap test. Specifically, 100.0% (6/6) of women with a repeat Pap 
showing HSIL were HPV positive compared with 83.3% (15/18) of women with a repeat 
Pap showing LSIL, 78.6% (11114) with a repeat Pap of ASCUS and 19.0% (11158) with a 
negative Pap test. Because the expected cell count for at least one cell was less than five, 
this trend could not be tested for significance. 
Table 6 shows the repeat Pap test results compared with HPV DNA testing results in the 
145 women who were referred to colposcopy with LSIL Pap test results. As with the 
women referred with an ASCUS Pap, the repeat Pap test results were heterogeneous for 
women who had been referred with an LSIL Pap in the community-based routine Pap 
screening. Only 37.2% (54/145) were again interpreted as having LSIL. However, the 
prevalence of HPV increased in parallel with the increasing severity of the repeat Pap test 
from 60.7% (37/61) in cases with negative Pap test results up to 100% (14/14) among 
those with a HSIL Pap test. Nevertheless, as with the ASCUS group, this trend could not 
be tested for significance because the expected cell count for at least one cell was less 
than five. 
4.4 Histological Diagnoses 
Histologically confirmed HSIL was present m 16.5% (16/97) and 20% (29/145) of 
women with ASCUS and LSIL baseline Pap results, respectively (Tables 7 and 8). No 
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Table 6: Association between repeat Pap and HPV DNA result in women referred 
with LSIL Pap results 
Repeat Pap 
Negative 
ASCUS 
LSIL 
ASC-H 
HSIL 
Total 
Positive 
(row%) 
HPV result 
37 (60.7) 
12 (80.0%) 
51 (94.4%) 
1 (100.0%) 
14 (100.0%) 
115 (79.3) 
Negative 
(row%) 
24 (39.3) 
3 (20.0%) 
3 (5.6%) 
0 (0.0%) 
0 (0.0%) 
30 (20.7) 
Total 
(column%) 
61 (42.1) 
15 (10.3) 
54 (37.2) 
1 (0.7) 
14 (9.7) 
145 (100.0) 
ASC-H = Atypical squamous cells, cannot exclude high-grade squamous intraepitheliallesion; ASCUS = 
Atypical squamous cells of undetermined significance; DNA = Deoxyribonucleic acid; HPV = Human 
papillomavirus; HSIL = High-grade squamous intraepitheliallesion; LSIL = Low-grade squamous 
intraepitheliallesion; Pap = Papanicolaou 
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Table 7: Association between histology and HPV DNA result in women referred 
with ASCUS Pap results, stratified by age 
HPV Result Histolog~ Significance* 
No. ofwomen No. ofwomen Total 
with HSIL with <LSIL 
All ages 
HPV (+) 16 (37.2%) 27 (62.8%) 43 p < 0.001 
HPV (-) 0(0.0%) 54 (100.0%) 54 
Age ~30 yrs 
HPV (+) 8 (47.1%) 9 (52.9%) 17 p < 0.001 
HPV (-) 0 (0.0%) 45 (100.0%) 45 
Age <30 yrs 
HPV (+) 8 (30.8%) 18 (69.2%) 26 P = 0.058 
HPV (-) 0 (0.0%) 9(100.0%) 9 
ASCUS = Atypical squamous cells of undetermined significance; DNA = Deoxyribonucleic acid; HPV = 
Human papillomavirus; HSIL = High-grade squamous intraepitheliallesion; LSIL = Low-grade squamous 
intraepitheliallesion 
*Fisher' s exact test for association ofHSIL confirmation with HPV positivity 
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Table 8: Association between histology and HPV DNA result in women referred 
with LSIL Pap results, stratified by age 
HPV Result Histologl: Significance 
No. ofwomen No. ofwomen Total 
with HSIL with <LSIL 
All ages 
HPV (+) 28 (24.3%) 87 (75.7%) 115 p < 0.05t 
HPV (-) 1 (3.3%) 29 (96.7%) 30 
Age ~30 yrs 
HPV (+) 9(30.0%) 21(70.0%) 30 P < O.OSt 
HPV (-) 0 (0.0%) 13 (100.0%) 13 
Age <30 yrs 
HPV (+) 19 (22.4%) 66 (77.6%) 85 p = 0.182t 
HPV (-) 1 (5.9%) 16 (94.1 %) 17 
DNA = Deoxyribonucleic acid; HPV = Human papillomavirus; HSIL = High-grade squamous 
intraepitheliallesion; LSIL = Low-grade squamous intraepitheliallesion 
tPearson chi-square test for association ofHSIL confirmation with HPV positivity 
tFisher's exact test for association ofHSIL confirmation with HPV positivity 
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cervical cancer was detected in any of the women. After stratification for age in the 
ASCUS group, histologically confirmed HSIL was found in 12.9% (8/62) of women 30 
years of age and older and in 22.9% (8/35) of those younger than 30 years (Table 7). In 
women with LSIL baseline cytology, 20.9% (9/43) of women 30 years and older and 
19.6% (20/102) of younger women were found to have underlying HSIL by histology 
(Table 8). 
4.5 Association of HPV and Histological Diagnoses 
Overall, there was a highly significant correlation (P < 0.001) between a positive test for 
HPV and a histological diagnosis of HSIL in women referred to colposcopy with ASCUS 
(Table 7). In this group, 16.5% (16/97) of the women were found to have underlying 
HSIL by histology, and HPV was detected in all of these women. Among women aged 
30 years and older, a strong association was also observed between HPV positivity and 
underlying HSIL by histology (P < 0.001). However, this association was not statistically 
significant in women younger than 30 years of age (P = 0.058), even though all 8 women 
with underlying HSIL by histology were positive for HPV. 
The association between histological diagnoses and HPV results among women with an 
LSIL baseline interpretation is shown in Table 8. Twenty-nine (20%) of the women had 
histologically confirmed HSIL. Among these women, all except one of the 29 cases of 
HSIL detected by histology occurred in women with an HPV positive result. In total, 
HPV positivity was associated with a seven-fold increase (24.3% vs. 3.3%) in the 
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histological diagnosis of HSIL (P < 0.05). When stratified by age, a strong association 
between histologically confirmed HSIL and HPV positivity was also seen in women 30 
years of age and older (P < 0.05). Among women younger than 30 years of age, the 
association between a positive HPV DNA test and underlying HSIL by histology was not 
statistically significant (P = 0.182), even though a higher percentage of women who were 
HPV positive were diagnosed with HSIL histology than those who were HPV negative 
(22.4% vs. 5.9%). 
4.6 Association of Repeat Pap Cytology and Histological Diagnoses 
The relationship between repeat Pap testing and histology in women referred with 
ASCUS is shown in Table 9. With the exception of a repeat Pap test result of ASCUS, 
the percentage of women with underlying HSIL by histology increased with the 
increasing severity of the repeat Pap category, from 6.8% in a negative result to 66.7% in 
HSIL. Because the expected cell count for at least one cell was less than five, this trend 
could not be tested for significance. 
The association between repeat Pap cytology results and histology in women referred 
with LSIL cytology are presented in Table 10. The percentage of women with 
underlying HSIL by histology increased with the increasing severity of the repeat Pap 
interpretation, from a range of 6.7 - 20.4% in negative or low-grade cytology categories 
to 78.6 - 100% in categories regarded as high-grade cytology. This trend could not be 
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Table 9: Association between repeat Pap and HSIL confirmation in women referred 
with ASCUS Pap results 
Repeat Pap 
Negative 
ASCUS 1 
LSIL1 
HSIL2 
Histology 
No. ofwomen with No. ofwomen with 
HSIL ~LSIL 
4 (6.8%) 55 (93.2%) 
5 (35.7%) 9 (64.3%) 
3 (16.7%) 15 (83.3%) 
4 (66.7%) 2 (33.3%) 
Total 
59 
14 
18 
6 
ASCUS = Atypical squamous cells of undetermined significance; HSIL = High-grade squamous 
intraepitheliallesion; LSIL = Low-grade squamous intraepitheliallesion; Pap = Papanicolaou 
1 Regarded as low-grade cytology 
2 Regarded as high-grade cytology 
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Table 10: Association between repeat Pap and HSIL confirmation in women 
referred with LSIL Pap results 
Repeat Pap 
Negative 
ASCUS1 
LSIL1 
ASC-H2 
HSIL2 
Histology 
No. of women with No. of women with 
HSIL :SLSIL 
5 (8.2%) 56 (91.8%) 
1 (6.7%) 14 (93.3%) 
11 (20.4%) 43 (77.8%) 
1 (100%) 0 (0.0%) 
11 (78.6%) 3 (21.4%) 
Total 
61 
15 
54 
1 
14 
ASC-H = Atypical squamous cells, cannot exclude high-grade squamous intraepitheliallesion; ASCUS = 
Atypical squamous cells of undetermined significance; HSlL = High-grade squamous intraepitheliallesion; 
LSIL = Low-grade squamous intraepitheliallesion; Pap = Papanicolaou 
1 Regarded as low-grade cytology 
2 Regarded as high-grade cytology 
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tested for significance because the expected cell count for at least one cell was less than 
five. 
4. 7 Performance of Different Triage Protocols 
On the basis of our data, we calculated the performance of three triage protocols in 
women referred to colposcopy with low-grade cytological abnormalities. 
Table 11 summarizes the performance indicators for detecting histologically confirmed 
HSIL and the percentage of women referred for colposcopy based on HPV DNA testing 
and repeat Pap cytology according to age for women referred with ASCUS. For all 
women, the most sensitive triage strategy would have been to refer those positive for 
HPV. HPV DNA testing detected 100% (95% CI = 79.4-100) of the cases of 
histologically confirmed HSIL. Repeat Pap testing showing ASCUS or more severe 
interpretation detected 75% of these cases (95% CI = 47.6-92.7), but this difference did 
not reach statistical significance. Repeat Pap testing at a higher threshold of LSIL would 
have resulted in a significantly lower sensitivity (43.8%; 95% CI = 19.8-70.1). The 
specificity, positive predictive value (PPV) and negative predictive value (NPV) of repeat 
Pap testing at the two thresholds of referral did not differ significantly from those of HPV 
DNA testing. All three triage strategies would have referred less than half of the women 
with ASCUS to colposcopy. 
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Table 11: Performance of HPV DNA testing and repeat cytology in detecting 
histologically confirmed HSIL in women with ASCUS Pap results, stratified by age 
HPV DNA testing Repeat Pap:~ASCUS Repeat Pap:~LSIL 
% (95% CI) % (95% CI) % (95% CI) 
All ages (16 HSILs)* 
Sensitivity 100.0 (79.4-100.0) 75.0 (47.6-92.7) 43.8 (19.8-70.1) 
Specificity 66.7 (55.3-76.8) 67.9 (56.6-77 .9) 79.0 (68.5-87.3) 
PPV 37.2 (23.0-53.3) 31.6 ( 17.5-48. 7) 29.2 (12.6-51.1) 
NPV 100.0 (93.4-100.0) 93.2 (83.5-98.1) 87.7 (77.9-94.2) 
Referral 44.3 (34.4-54.2) 39.2 (29.5-48.9) 24.7 ( 16.2-33 .3) 
Age ~30 yrs (8 HSILs) 
Sensitivity I 00.0 (63.1-1 00.0) 75.0 (34.9-96.8) 50.0 (15.7-84.3) 
Specificity 83.3 (70.7-92.1) 81 .5 (68.6-90.8) 87.0 (75.1-94.6) 
PPV 47.1 (23.0-72.2) 37.5 (15.2-64.6) 36.4 (I 0.9-69.2) 
NPV I 00.0 (92.1-1 00.0) 95.7 (85.2-99.5) 92.2 (8 1.1-97.8) 
Referral 27.4 (16.3-38.5) 25.8 (14.9-36.7) 17.4 (8.2-27.3) 
Age <30 yrs (8 HSILs) 
Sensitivity 100.0 (63.1-100.0) 75.0 (34.9-96.8) 37.5 (8.5-75.5) 
Specificity 33.3 ( 16.5-54.0) 40.7 (22.4-61 .2) 63.0 ( 42.4-80.6) 
PPV 30.8 (14.3-51.8) 27.3 (10.7-50.2) 23.1 (5.0-53.8) 
NPV 100.0 (66.4-1 00.0) 84.6 (54.6-98.1) 77.3 (54.6-92.2) 
Referral 74.3 (59.8-88.8) 62.9 ( 46.8-78.9) 37.1 (21.1 -53 .2) 
ASCUS = Atypical squamous cells of undetermined sign ificance; Cl = Confidence interval; DNA = 
Deoxyribonucleic acid; HPV = Human papillomavirus; HSIL = High-grade squamous intraepithelial 
lesion; LSIL = Low-grade squamous intraepithelial lesion; Pap = Papanicolaou; PPV = Positive predictive 
value; NPV = Negative predictive value 
*Number of women with histologically confirmed HSIL 
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When stratified by age, the specificity of a positive HPV DNA test differed considerably 
between the two age categories of women, whereas the sensitivity and NPV remained the 
same at 100% (Table 11). In women younger than 30 years of age, the HPV DNA test 
revealed a significantly lower specificity than in older women (33.3%; 95% CI = 16.5-
54.0 and 83.3%; 95% CI = 70.7-92.1 respectively). Among these older women, only 
27.4% (95% CI = 16.3-38.5) would have been referred for colposcopy, a difference of 
more than 45% compared with women younger than 30 years (74.3%; 95% CI = 59.8-
88.8). For repeat cytology at both referral thresholds, sensitivity, NPV and PPV did not 
differ significantly between the two age categories. However, specificity of repeat 
cytology of ASCUS or worse was significantly higher in older women compared with 
those younger than 30 years (81.5%; 95% CI = 68.6-90.8 and 40.7%; 95% CI = 22.4-61.2 
respectively). 
Table 12 summarizes the performance indicators of HPV DNA testing and repeat Pap 
testing for women referred with LSIL and stratified by age. The most sensitive triage 
strategy for all women was HPV DNA testing, correctly identifying 96.6% (95% CI = 
82.2-99.9) of women with underlying HSIL by histology. However, the difference in 
sensitivities between the three triage protocols did not reach statistical significance. The 
specificity of HPV DNA testing was significantly lower than repeat Pap cytology at both 
thresholds for referral. The PPV and NPV varied minimally among the triage protocols, 
while HPV DNA testing would have required the referral of significantly more women 
than repeat Pap cytology. 
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Table 12: Performance of HPV DNA testing and repeat cytology in detecting 
histologically confirmed HSIL in women with LSIL Pap results, stratified by age 
HPV DNA testing Repeat Pap:2':ASCUS Repeat Pap:2':LSIL 
% (95% CI) % (95% CI) % (95% CI) 
All ages (29 HSILs)* 
Sensitivity 96.6 (82.2-99.9) 82.8 (64.2-94.2) 79.3 (60.3-92.0) 
Specificity 25.0 (17.4-33.9) 48.3 (38.9-57.7) 60.3 (50.8-69.3) 
PPV 24.3 (16.8-33.2) 28.6 (19.2-39 .5) 33.3 (22.4-45.7) 
NPV 96.7 (82.8-99.9) 91.8 (81.9-97.3) 92.1 (83.6-97.1) 
Referral 79.3 (72.7-85.9) 57.9 (49.9-66.0) 47.6 (39.5-55.7) 
Age 2':30 yrs (9 HSILs) 
Sensitivity 100.0 (66.4-100.0) 100.0 (66.4-1 00.0) 100.0 (66.4-1 00.0) 
Specificity 38.2 (22.2-56.4) 44.1 (27.2-62.1) 52.9 (35.1-70.2) 
PPV 30.0 (14.7-49.4) 32.1 (15.9-52.4) 36.0 (18.0-57.5) 
NPV I 00.0 (75.3-1 00.0) 100.0 (78.2-1 00.0) I 00.0 (81 .5-1 00.0) 
Referral 69.8 (56.0-83.5) 65.1 (50.9-79.4) 58.1 ( 43.4-72.9) 
Age <30 yrs (20 HSILs) 
Sensitivity 95.0 (75.1-99.9) 75.0 (50.9-91.3) 70.0 (45.7-88.1) 
Specificity 19.5 (11.6-29.7) 50.0 (38.8-61.3) 63.4 (52.1-73.8) 
PPV 22.4 ( 14.0-32. 7) 26.8 ( 15.8-40.3) 31.8 (18.6-47.6) 
NPV 94.1 (71.3-99.9) 89.1 (76.4-96.4) 89.7 (78.8-96.1) 
Referral 83.3 (76.1-90.6) 54.9 (45.2-64.6) 43.1 (33.5-52.7) 
ASCUS = Atypical squamous cells of undetermined significance; CI = Confidence interval; DNA = 
Deoxyribonucleic acid; HPV = Human papillomavirus; HSIL = High-grade squamous intraepithelial 
lesion; LSIL = Low-grade squamous intraepithelial lesion; Pap = Papanicolaou; PPV = Positive predictive 
value; NPV = Negative predictive value 
*Number of women with histologically confrrmed HSIL 
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When stratified by age, the sensitivity and NPV of all three triage protocols was 100% 
among women 30 years of age and older, with statistically non-significant declines in 
younger women (Table 12). The specificity of the HPV DNA test was higher in older 
women, but it was not significantly different from younger women. Based on HPV DNA 
testing, colposcopy referrals would have declined only slightly among women 30 years of 
age and older, from 83.3% (95% CI = 76.1-90.6) in younger women to 69.8% (95% CI = 
56.0-83.5). For repeat cytology at both referral thresholds, specificity and the referral 
rate did not differ significantly between the two age categories. 
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5.1 Introduction 
CHAPTERV 
DISCUSSION 
This retrospective cohort study was carried out to: (1) describe the association of human 
papillomavirus (HPV), repeat Papanicolaou (Pap) cytology and histology results in 
women with low-grade cytological abnormalities; (2) assess the performance of the HPV 
deoxyribonucleic acid (DNA) test in triage of women with low-grade cytological 
abnormalities, namely atypical squamous cells of undetermined significance (ASCUS) 
and low-grade squamous intraepitheliallesions (LSIL); (3) assess the performance of the 
repeat Pap test in triage of women with low-grade cytological abnormalities, namely 
ASCUS and LSIL; (4) compare the performance of both triage tests; and (5) determine if 
age affects triage performance. 
5.2 HPV Prevalence 
The prevalence of HPV in the present study population is similar to that from other 
published research using the Hybrid Capture II (HC-11) assay (Digene Corporation, 
Gaithersburg, Maryland, USA) (AL TS Group, 2000; Manos et al., 1999; Solomon et al., 
2001). In the current study, 44.3% of women with ASCUS Pap test results were positive 
for HPV, thereby potentially reducing the number of women with ASCUS cytology who 
are referred to colposcopy by more than one half. Manos et al. (1999) reported a HPV 
prevalence of 39.5% and the ALTS trial demonstrated a slightly higher HPV prevalence 
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of 56.1% (Solomon et al., 2001). In contrast, the prevalence ofHPV in our study sample 
was significantly higher in women with a referral Pap test result of LSIL (79.3%) (P < 
0.001) than in women with an ASCUS cytology interpretation (44.3%). A recent review 
article suggests that HPV prevalence rates in LSIL cytology were consistently higher than 
in ASCUS cytology (Arbyn et al., 2006). Other studies have also reported similar levels 
of HPV prevalence in LSIL cytology (Clavel et al. , 1999; AL TS Group, 2000). Clave} et 
al. (1999) found that 76.8% of women with LSIL in their study were HPV positive. In 
the AL TS trial, HPV was detected in 82.9% of women with LSIL, and consequently, they 
closed the enrollment of women to the HPV arm of the study early (AL TS Group, 2000). 
Because of the high prevalence of HPV in women with LSIL cytology, they concluded 
that an LSIL cytology result is likely indicative of HPV infection, and it appears that 
there is limited potential for the use of HPV DNA testing in triage for the evaluation of 
LSIL. 
HPV prevalence was clearly age-dependent in women with an ASCUS Pap test result, 
being significantly higher among women younger than 30 years of age (74.3%) than 
older women (27.4%) (P < 0.001). On the other hand, this age distinction seems to be 
not as great in women with an LSIL interpretation, where HPV prevalence is high in both 
younger (83 .3%) and older women (69.8%) (P = 0.065). Nevertheless, the decreasing 
prevalence of HPV with age is consistent with the natural history of HPV infection and is 
similar to previous studies (Ho et al., 1998; Sherman et al., 2002; Shlay et al., 2000). 
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5.3 Association between HPV and Repeat Cytology 
Among women referred with ASCUS cytology, repeat Pap results were heterogeneous. 
Only 14.4% of repeat Pap tests were read as ASCUS. Repeat Pap results were also 
heterogeneous among women referred with LSIL cytology. However, a higher 
percentage of LSIL results were again LSIL when repeated (37.2%). These findings 
reflect those of other research elsewhere that ASCUS results are less reproducible than 
LSIL results (Stoler & Schiffman, 2001). 
In the present study, the prevalence of HPV increased with the increasing severity of the 
repeat Pap test result in women with baseline cytology of ASCUS and LSIL. We could 
not test this trend because the expected cell count for at least one cell was less than five. 
Other studies, however, were able to test this trend. Solomon et al. (200 1 ), reported that 
among women with ASCUS, the trend towards increasing HPV positivity with increasing 
severity of repeat cytology diagnoses was significant (P < 0.001 ). The AL TS Group 
(2003b) also found a significant trend (P < 0.001) in a group of women with LSIL 
cytology. 
5.4 Association between HPV, Repeat Cytology and Histology 
Women referred for an ASCUS Pap abnormality generally have a lower prevalence of 
histologically diagnosed high-grade squamous intraepithelial lesions (HSIL) than do 
women referred for a LSIL Pap abnormality (ALTS Group, 2003a; AL TS Group, 2003b; 
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Lytwyn et al., 2000; Sherman et al., 2002). In the present study, the overall prevalence of 
histologically diagnosed HSIL in women with ASCUS was 16.5%. Solomon et al. 
(2001) reported a similar percentage (15.4%). In women with LSIL Pap test results, we 
found 20% to have underlying HSIL. The overall detection of HSIL as diagnosed by 
histology in the AL TS trial was slightly higher at 25% (AL TS Group, 2003 b). However, 
the rate reported by the ALTS study was a cumulative 2-year percentage, whereas our 
study followed up for only one year. These findings indicate that women with low-grade 
cytological abnormalities require some form of additional evaluation and follow-up. 
A significant association (P < 0.001) was found between a positive HPV result and 
underlying HSIL in women with ASCUS cytology. All women with a histological 
diagnosis of HSIL were HPV positive. When stratified by age, however, the association 
between HPV and confirmed HSIL was no longer significant among women younger 
than 30 years of age (P = 0.058). This was likely due to the small sample size. 
In women with a referral diagnosis of LSIL, there was also a significant association 
between HPV positivity and HSIL confirmation (P < 0.05). Among these women, all 
except one of the 29 cases of HSIL detected by histology occurred in women with an 
HPV positive result. This single exception may represent a woman with a regressing 
lesion who already had cleared the virus. It is also possible that the HPV negative case 
may have been due to false negative results as a result of low viral copy number or poor 
sample collection. When stratified by age, there was no longer a statistically significant 
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association between HPV and histological HSIL among women younger than 30 years of 
age (P = 0.182). Again, the failure to reach significance is likely due to the small study 
sample. 
In women with a baseline Pap result of ASCUS or LSIL, the percentage with HSIL by 
histology increased with the increasing severity of the repeat Pap category. However, 
because the expected cell count for at least one cell was less than five, this trend could 
not be tested. Previous research has shown that the more severe the Pap category, the 
greater the risk of having underlying HSIL (Kinney et al. , 1998). 
5.5 Performance of Different Triage Protocols 
5.5.1 Triage of ASCUS Cytology 
In assessing the performance indicators in women with baseline ASCUS cytology, we 
found that a single HPV DNA test would have appropriately triaged 100% of the women 
who had a histological diagnosis ofHSIL, while referring only 44.3% of the total ASCUS 
population with a negative predictive value (NPV) of 100%. The relatively low 
prevalence of HPV in women with ASCUS, combined with the high sensitivity and NPV 
of the HPV DNA test, is compatible with the Canadian and American recommendations 
to use HPV DNA testing as an immediate adjunct screening test for triage of ASCUS Pap 
cytology results (Provencher & Murphy, 2007; Stuart et al. , 2004; Wright et al., 2007). 
The strategy of repeat cytology was less sensitive (75%) than the HPV DNA test in 
detecting underlying HSIL at an ASCUS threshold of referral, referring 39.2% of women. 
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Although repeat cytology at a LSIL threshold of referral would have referred the least 
number of women to colposcopy (24.7%), it was the most insensitive triage strategy, 
identifying only 43.8% of underlying HSIL. These results are similar to those of 
previous research (Arbyn et al., 2004; Manos et al., 1999; Solomon et al. , 2001). 
Manos et al. ( 1999) compared HPV DNA testing to repeat Pap testing in a sample of 995 
women with ASCUS. All women had specimens taken for a repeat Pap test and HPV 
DNA testing, followed by a colposcopically-directed biopsy to confirm the diagnoses. 
As in the present study, the gold standard was a histological diagnosis of HSIL or cancer 
since the current clinical practice is to treat histologically confirmed HSIL, in addition to 
cancer. The sensitivity of the HPV DNA test was 89.2% for detection of underlying 
HSIL or cancer. This was higher than repeat Pap testing at an ASCUS threshold of 
referral which had a sensitivity of 76.2%. However, the specificity of HPV DNA testing 
was similar to that of repeat cytology (64.1% and 63.8%, respectively). It was estimated 
that triage based on HPV DNA testing or on repeat Pap testing with referral to 
colposcopy set at a repeat Pap result interpreted as ASCUS or more severe, would have 
resulted in approximately the same number of referrals for colposcopy (40%). The 
authors concluded that for women with ASCUS Pap results, the HPV DNA test can help 
identify the majority of women with underlying HSIL or cancer. 
The ALTS Group compared three management strategies, immediate colposcopy, HPV 
DNA triage with referral if positive, or triage based on repeat Pap testing in 3,488 women 
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with ASCUS (Solomon et al., 2001). The sensitivities of immediate colposcopy, HPV 
DNA triage, and repeat Pap at an ASCUS threshold of referral were 100, 95.9, and 
85.0%, respectively. Just over half (56.1 %) of the women having HPV DNA testing 
would have been referred to colposcopy, and 58.6% of the women having a single repeat 
Pap test would have been referred. Given that the HPV DNA test showed a greater 
sensitivity for detection of histologically confirmed HSIL or cancer than a single repeat 
Pap at a threshold of ASCUS or worse (95.9% and 85.0%, respectively), and a 
comparable specificity (48.4% and 44.7%, respectively), the authors concluded that HPV 
DNA testing is an option for managing women with ASCUS to determine if colposcopy 
is needed. Nevertheless, the referral rate of women by HPV DNA testing is still high 
compared to the low percentage of true HSIL diagnosed in women with ASCUS. 
Arbyn et al. (2004) recently conducted a meta-analysis that compared HPV DNA testing 
with repeat Pap testing for triaging ASCUS. They reported that restriction of colposcopy 
examination to women with a positive HPV DNA test had a sensitivity of 94.8% for 
underlying HSIL, compared with 81.8% for repeat cytology at an ASCUS threshold. 
The fact that differences in age distribution may affect the performance of the HPV DNA 
test became apparent in this study. We found that in women younger than 30 years of 
age, the HPV DNA test showed a significantly lower specificity than in older women 
(33.3% and 83.3%, respectively). The poor specificity in younger women is reflective of 
the high prevalence of HPV in this age group. On the other hand, the sensitivity and 
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NPV were largely unaffected by age. HPV DNA testing would have shown a significant 
reduction in referrals to colposcopy among women 30 years of age and older compared to 
younger women (27.4% and 74.3%, respectively). However, had we restricted HPV 
testing to women 30 years of age and older, 8 women younger than 30 years of age with 
HSIL by histology would not have been referred to colposcopy. 
The association between age and HPV test performance in our study is consistent with 
that observed in other studies (Rebello, Hallam, Smart, Farquharson, McCafferty, 2001 ; 
Sherman et al., 2002; Shlay et al., 2000). In a study by Rebello et al. (2001), the 
sensitivity was 94% in women under 30 years of age versus 91% among women at least 
30 years old, while the specificity was 33% and 72% in younger versus older women, 
respectively. Shlay et al. (2000) reported that the specificity was 57.4% in women under 
30 years of age versus 83.9% among women at least 30 years old. However, the 
sensitivity was somewhat lower in older women (85.7% in women ~30 years and 100% 
women in <30 years, respectively). Sherman et al. (2002) reported that sensitivity varied 
minimally with age (range, 93.9% to 97.8%) and specificity increased with age. In age 
groups 18-22, 23-28 and 29 and older the specificity was 34%, 41% and 52%, 
respectively. Consistent with the present study, HPV testing in these studies all 
demonstrated a significant reduction in referrals between older and younger women. 
The results for repeat Pap cytology in the current study demonstrated similar differences 
in performance indicators when stratified by age, as was seen for HPV DNA testing. The 
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sensitivity of repeat cytology at an ASCUS threshold of referral remained the same in 
both age groups, and like HPV testing, the test was significantly more specific in women 
30 years of age and older (81.5% in women ~ 30 years and 40.7% in women < 30 years, 
respectively). Nevertheless, HPV DNA testing remained the most sensitive test among 
all age groups. 
5.5.2 Triage of LSIL Cytology 
Unlike women with baseline ASCUS cytology, we did not find an appropriate triage 
method for women with LSIL of any age. A single HPV DNA test would have 
appropriately triaged 96.6% of the women who were found to have HSIL as diagnosed by 
histology, but the test would have referred the greater majority (79.3%) of the total LSIL 
population, limiting its usefulness for triage of these women. A program of triage is 
generally not considered acceptable if 75% or more of women tested would be referred to 
colposcopy because of a positive result (Wright et al. , 2007). As discussed previously, 
the AL TS Group (2000) closed the enrollment of women to the HPV arm of their study 
due to the high prevalence of HPV in the LSIL population (82.9%). Consistent with 
previous results of women with LSIL cytology (Sherman et al., 2002), the percentage of 
women with positive HPV results did not decline substantially with age. Approximately 
70% of women at least 30 years of age would still have been referred by this triage 
method. 
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In examining the performance of repeat cytology in women with LSIL, repeat cytology at 
a threshold of ASCUS would have referred 57.9%; however, the sensitivity of this 
approach was low at 82. 8%. In fact, in any age group and for both thresholds of repeat 
cytology, either method that had a good sensitivity required referral of the majority of 
women. 
When the AL TS Group (2003 b) estimated the performance of repeat cytology in women 
with LSIL, a single repeat Pap result at the ASCUS threshold referred more than 80%. 
They concluded that this percentage was too high to justify the use of repeat cytology for 
the triage of these women. 
5.6 Strengths and Limitations of Study 
There are strengths and limitations with the current study. The main strength of this 
study was the opportunity to evaluate the utility of the HPV DNA test in triage of women 
with low-grade cytological abnormalities in Newfoundland, Canada. This is one of few 
studies in Canada that have examined the HPV test in triage of these women. The 
opportunity to assess HPV DNA testing in secondary screening presents new options for 
the cervical cancer screening programme. Lytwyn et al. (2000) conducted a study 
comparing HPV DNA testing and repeat Pap testing in 212 women from Ontario with 
ASCUS and LSIL cytology. They found the HPV DNA test to be more sensitive (87.5%) 
than repeat cytology (55.6%) at an ASCUS threshold for referral in these women. 
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However, they reported the performance of the tests without distinguishing between 
women with ASCUS or LSIL. 
This study does have limitations. A reliable gold standard was not available for all 
women in the study. Ideally, all women should have undergone colposcopy and biopsy 
to determine disease status. However, because this was a retrospective cohort study and 
not a randomized control trial, histology was taken at the clinician's discretion. It is 
likely that a number of women did not undergo biopsies because of a negative 
colposcopy, and this is an indication of no disease. However, some research suggests 
that the accuracy of colposcopy is imperfect (Barker, Garcia, Warner, Lozerski, & Hatch, 
2002; Massad & Collins, 2003). 
The small sample size was also a limitation. Some statistical tests could not be carried 
out because of the small numbers. This may help explain why certain significant 
associations or differences were not observed. However, while the small sample size 
could also limit the generalizability of the conclusions, the findings of this study are 
similar to those of large randomized trials. 
A further limitation is that the study does not take into account regression, persistence, or 
progression of HPV infection, or histological outcomes. 
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Finally, we did not distinguish between women with a history of abnormal cytology and 
those without one. This may have influenced the performance of the HPV DNA test. 
However, other published studies have found there to be no difference in HPV DNA test 
performance in women independent of history of cytological abnormalities. (Manos et al. , 
1999; Shlay et a!., 2000). 
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CHAPTER VI 
CONCLUSIONS AND RECOMMENDATIONS 
This study confirms that human papillomavirus (HPV) deoxyribonucleic acid (DNA) 
testing can be used to triage women with atypical squamous cells of undetermined 
significance (ASCUS). The HPV DNA test reached 100% sensitivity for detection of 
underlying high-grade intraepithelial lesions (HSIL) and would have reduced referrals to 
44.3%. The specificity of this approach was at 66.7%, but when stratified by age, 
specificity increased significantly in older women (83.3% in women ~ 30 years and 
33.3% in women < 30 years, respectively). As well, referrals to colposcopy would have 
been significantly reduced among older women compared to younger women (27 .4% and 
74.3%, respectively). However, restricting HPV testing to women 30 years of age and 
older would have resulted in eight out of the sixteen women with HSIL by histology not 
being referred to coloposcopy. Further study should be untaken to investigate the 
usefulness of age-restricted HPV testing, examining various age thresholds of referral. 
Repeat cytology for women with ASCUS was estimated to be a less sensitive (75%) 
approach for triaging women in all age groups. 
In contrast to ASCUS, we did not find a suitable triage strategy for women with low-
grade squamous intraepithelial lesion (LSIL) cytology. Approximately 80% of these 
women were positive for HPV, and this percentage did not decline substantially with age. 
In women 30 years of age and older, the HPV prevalence was 69.8% and in women 
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younger than 30 years of age, the prevalence of HPV was 83.3%. Because of this high 
HPV prevalence, triage using HPV DNA testing may not be useful for the LSIL 
population. Repeat cytology using either an ASCUS or LSIL threshold of referral was 
also determined to be an ineffective method of triage in any age group. Any method that 
had a good sensitivity (approximately 90%) required referral of the majority 
(approximately 60%) of women. It is therefore recommended, as is the recommendation 
of others (Wright et al., 2007), that women with LSIL Pap results be referred to 
colposcopy immediately. 
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